Ulta Beauty To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Wall Street analysts updated ratings for top names. Workday target raised, Ulta Beauty & Genasys targets lowered. See how others view these stocks.
Stocks · News reference
Generate Biomedicines shares are trading lower after the company reported mixed Q2 financial results.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $25 to $30.
8-K filing — Generate Biomedicines, Inc. (GENB)
Filed: 2026-08-26 AccNo: 0001193125-26-365556 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits